Navigation Links
Cardiome to Present at ThinkEquity Conference
Date:9/17/2007

NASDAQ: CRME TSX: COM

VANCOUVER, Sept. 17 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: CRME/TSX: COM) today announced that Bob Rieder, Chairman and Chief Executive Officer, will present an overview of Cardiome at the ThinkEquity Partners Annual Growth Conference in San Francisco at 8:00am Pacific Time (11:00am Eastern Time) on Wednesday, September 19, 2007.

A live webcast of Mr. Rieder's presentation can be accessed on Cardiome's website at http://www.cardiome.com. A replay of the webcast will be posted after the presentation and will be available until October 19, 2007.

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with two late-stage clinical drug programs focused on atrial arrhythmia (intravenous and oral dosing), a Phase 1 program for GED-aPC, an engineered analog of recombinant human activated Protein C, and a pre-clinical program directed at improving cardiovascular function.

Vernakalant (iv) is the intravenous formulation of an investigational drug being evaluated for the acute conversion of atrial fibrillation (AF). Positive top-line results from two pivotal Phase 3 trials for vernakalant (iv), called ACT 1 and ACT 3, were released in December 2004 and September 2005. Cardiome's co-development partner Astellas Pharma US, Inc. submitted a New Drug Application for vernakalant (iv) in December 2006. Positive top-line results from an additional Phase 3 study evaluating patients with post-operative atrial arrhythmia, called ACT 2, were released in June 2007. An open-label safety study evaluating recent-onset AF patients, called ACT 4, has completed.

Vernakalant (oral) is being investigated as a chronic-use oral drug for the maintenance of normal heart rhythm following termination of AF. Cardiome announced positive results from a Phase 2a pilot study for vernakalant (oral) in September 2006. A Phase 2b study for vernakalant (oral) is ongoing.

In April 2007 Cardiome acquired exclusive worldwide rights for GED-aPC for all indications. Cardiome intends to initially develop GED-aPC in cardiogenic shock, a life-threatening form of acute circulatory failure due to cardiac dysfunction, which is a leading cause of death for patients hospitalized following a heart attack.

Cardiome is traded on the Toronto Stock Exchange (COM) and the NASDAQ National Market (CRME).

Forward-Looking Statement Disclaimer

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: we may not be able to successfully develop and obtain regulatory approval for vernakalant (iv) or vernakalant (oral) in the treatment of atrial fibrillation or any other current or future products in our targeted indications; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and sales capabilities and the costs of launching our products may be greater than anticipated; we rely on third parties for the continued supply and manufacture of vernakalant (iv) and vernakalant (oral) and we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Securities and Exchange Commission available at http://www.sec.gov and the Canadian securities regulatory authorities at http://www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

CONTACT: Peter K. Hofman, Senior Director, Investor Relations, (604) 676-6993 or Toll Free: 1-800-330-9928, Email: phofman@cardiome.com


'/>"/>
SOURCE Cardiome Pharma Corp.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Anti-obesity Drugs Claimed Additional Benefits on cardiometabolic Risk Factors Questioned
2. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
3. Researchers Present Ways To Reduce The Risk Of Dementia
4. Researchers Present Data Regarding The Efficiency Of Herbs
5. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
6. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
7. Drug Reactions First Present Themselves In The Mouth
8. Reminiscing Into The Past Makes You Dissatisfied With The Present
9. Living In The Past Indicates Dissatisfaction With Present
10. Movies Represent Coma In A Wrong Way
11. Onchocerciasis: Presentation And Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... Portland, Maine (PRWEB) , ... April 28, 2016 , ... ... of death and principal determinant of childhood mortality. This is particularly true in underdeveloped ... A lecture at the University of New England’s campus in Tangier, Morocco, will examine ...
(Date:4/28/2016)... ... 28, 2016 , ... Cognizin® Citicoline is one of three ... the Healthy Ageing category, Cognizin® is being considered for this prestigious honor due ... include everything from antioxidants, lipids, proteins, and botanicals. NutraIngredients will choose a winner ...
(Date:4/28/2016)... ... April 28, 2016 , ... The ... Education and Anzu®, developers of the AnzuMedical™ Knowledge Sharing and Collaboration Platform™ ... Residency Network. The platform is scheduled to launch in July 2016 and will ...
(Date:4/28/2016)... ... April 28, 2016 , ... April, 28, 2016 – ... in Physical Medicine and Rehabilitation by Philadelphia Magazine. , Philadelphia Magazine’s annual Top ... surveying physicians and medical leadership across the country. These select individuals nominate outstanding ...
(Date:4/28/2016)... ... 28, 2016 , ... Starting today, households across the United ... Medical Prescription Assistance Program. They are customized to reflect the specific health needs ... a ready-to-use, state-themed card and, in the near future, material that highlights savings ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... YORK , April 28, 2016  The blood ... 275 million dollars, according to Kalorama Information and The ... typing, immunoassays and nucleic acid testing.  The healthcare research ... made progress in developing blood collection stations and in ... made in Kalorama Information,s report, Blood Testing ...
(Date:4/28/2016)... Dr. Vivek Ahuja , ... phen Schmidt Join the Growing ... solutions for life sciences, today announced key new leaders have joined ... to a growing business.  This will bolster the company,s safety business ... joined ArisGlobal in the position of Vice President - Safety. George ...
(Date:4/28/2016)... FREMONT, Calif. , April 28, 2016 ... Enterprise Validation Lifecycle Management Solutions (VLMS) today ... products and services for sufferers of chronic ... management System to manage their corporate validation ... been seeking a software solution to manage ...
Breaking Medicine Technology: